尽管收入和收益低于竞争对手，但 Oruka Therapeutics 拥有更高的共识评级和更强的机构所有权。 Oruka Therapeutics has a higher consensus rating and stronger institutional ownership despite lower revenue and earnings than competitors.

Oruka治疗学(ORKA)专门研究针对心脏衰竭和心血管疾病的转基因疗法。 Oruka Therapeutics (ORKA) specializes in genetically-targeted therapies for heart failure and cardiovascular diseases. 尽管收入和收入低于竞争者,但它的共识评级更强,机构所有权也更高,为56.4%。 Despite lower revenue and earnings than competitors, it has a stronger consensus rating and higher institutional ownership at 56.4%. 在13个比较系数中,Oruka在10个中表现优异,但贸易价格与收入比率较高。 Oruka excels in 10 of 13 comparison factors but trades at a higher price-to-earnings ratio. 相比之下，Intellia Therapeutics 在七个因素上表现出更好的表现，包括更高的机构所有权和潜在的上行空间。 In contrast, Intellia Therapeutics shows better performance in seven factors, including higher institutional ownership and potential upside.